Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome

Journal of Cardiovascular Medicine

Volumn 7, Issue 3, 2006, Pages 159-165

  De Servi, Stefano ^a   Mariani, Matteo ^a   Vandoni, Pietro ^a   Dellavalle, Antonio ^b   Politi, Alessandro ^c   Poletti, Fabrizio ^a   Bonizzoni, Erminio ^d   Leoncini, Mario ^e   Cavallini, Claudio ^f  

^a Ospedale Civile di Legnano   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e OSPEDALE CA FONCELLO   (Italy)

^f MISERICORDIA E DOLCE HOSPITAL   (Italy)

Author keywords

Acute coronary syndromes; Antiplatelet agents; Glycoprotein IIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; TIROFIBAN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; TYROSINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; BLEEDING; CORONARY CARE UNIT; DIABETES MELLITUS; DRUG FATALITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON Q WAVE MYOCARDIAL INFARCTION; NON ST ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; Q WAVE; REGISTER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ST SEGMENT DEPRESSION; STROKE; DRUG ANTAGONISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; STENT; SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REGISTRIES; STENTS; SYNDROME; TYROSINE;

EID: 33646852221     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000215269.47520.75     Document Type: Article

References (24)

1. Boersma E, Harrington RA, Moliterno DJ, White H, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189-198.
2. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit related to the revascularization strategy. Eur Heart J 2002; 23:1441-1448.
3. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. N Engl J Med 1998; 339:436-443.
4. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497.
5. The GUSTO-IV ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO-IV ACS randomised trial. Lancet 2001; 357:1915-1924.
6. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al., for the TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894.
7. Antman EM.Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of Guidelines. Am Heart J 2003; 146:S18-S22.
8. The ROSAI-2 Investigators. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective ROSAI-2 registry. Ital Heart J 2003; 4:782-790.
9. De Servi S, Cavallini C, Dellavalle A, Santoro GM, Bonizzoni E, Marzocchi A, et al., for the ROSAI-2 Investigators. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. Am Heart J 2004; 147:830-836.
10. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284:835-842.
11. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non ST-elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). Circulation 2000; 102:1193-1209.
12. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al., for the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without ST-segment elevation. Eur Heart J 2002; 23:1809-1840.
13. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349:1429-1435.
14. Petersen ED, Pollack CV, Roe MT. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction. Observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 2003; 42:45-53.
15. Budaj A, Brieger D, Steg PG, Goodman SG, Dabbous OH, Fox KA, et al., for the GRACE Investigators. Global patterns of use of antithrombotic and antiplatelets therapies in patients with acute coronary syndromes: insight from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003; 146:999-1006.
16. Januzzi JL, Cannon CP, Theroux P, Boden WE. Optimizing glycoprotein IIb/IIIa antagonists use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Am Heart J 2003; 146:764-774.
17. The FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354:708-715.
18. Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, et al. Low-molecular weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002; 144:615-624.
19. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation 2001; 104:2767-2771.
20. Bhatt DL, Marso SP, Lincoff M, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35:922-928.
21. Sabatine MS, Morrow DE, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 Trial. Circulation 2004; 109:874-880.
22. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al., for the TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879-1887.
23. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994; 89:1545-1556.
24. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.